Indeed, CD38 expression is also reduced in patients with sustained high quality response, suggesting that CD38 reduction is not necessarily associated with escape from daratumumab-mediated killing, but indicates that the pressure to keep MM cells in a state of low CD38 expression, may also offer clinical benefit. The gene discussed is CD38; the disease is Miyoshi myopathy.